> top > docs > PubMed:32267771 > annotations

PubMed:32267771 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 1384-1391 SO:0000417 denotes domains
T2 1393-1404 CHEBI:33282 denotes antibiotics
T3 1393-1404 CHEBI:33282 denotes antibiotics
T4 1475-1484 CHEBI:25106 denotes macrolide
T5 1475-1484 CHEBI:25106 denotes macrolide
T6 1510-1524 CHEBI:50858 denotes corticosteroid
T7 1510-1524 CHEBI:50858 denotes corticosteroid
T8 1851-1862 GO:0015671 denotes oxygenation
T9 1947-1958 UBERON:0001004 denotes respiratory
T10 2165-2173 SP_7 denotes COVID-19
T11 2191-2198 GO:0007612 denotes learned

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 80-89 Disease denotes Pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T2 616-625 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T3 1428-1437 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T4 1786-1805 Disease denotes influenza infection http://purl.obolibrary.org/obo/MONDO_0005812
T5 1796-1805 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T6 1947-1969 Disease denotes respiratory infections http://purl.obolibrary.org/obo/MONDO_0024355
T7 2165-2173 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 382-383 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 648-649 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 672-673 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 747-750 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T5 955-956 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 1183-1184 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 1878-1881 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T8 2040-2042 http://purl.obolibrary.org/obo/CLO_0001407 denotes 52

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 1393-1404 Chemical denotes antibiotics http://purl.obolibrary.org/obo/CHEBI_33281
T2 1406-1415 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T3 1475-1484 Chemical denotes macrolide http://purl.obolibrary.org/obo/CHEBI_25106
T4 1510-1524 Chemical denotes corticosteroid http://purl.obolibrary.org/obo/CHEBI_50858

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 80-89 Phenotype denotes Pneumonia http://purl.obolibrary.org/obo/HP_0002090
T2 616-625 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T3 1756-1761 Phenotype denotes shock http://purl.obolibrary.org/obo/HP_0031273
T4 1947-1969 Phenotype denotes respiratory infections http://purl.obolibrary.org/obo/HP_0011947

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-108 Sentence denotes The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study:
T2 109-130 Sentence denotes Rationale and Design.
T3 131-336 Sentence denotes There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies.
T4 337-632 Sentence denotes Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia (CAP).
T5 633-735 Sentence denotes The trial uses a novel design entitled a randomized embedded multifactorial adaptive platform (REMAP).
T6 736-1308 Sentence denotes The design has 5 key features: i.) randomization, allowing robust causal inference; ii.) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; iii.) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; iv.) response-adaptive randomization with preferential assignment to those interventions that appear most favorable, and v.) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments.
T7 1309-1571 Sentence denotes The trial randomizes patients to multiple interventions within 4 treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens.
T8 1572-1806 Sentence denotes The trial generates estimates of superiority, inferiority and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection.
T9 1807-1970 Sentence denotes The trial will also compare ventilatory and oxygenation strategies and has capacity to address additional questions rapidly during pandemic respiratory infections.
T10 1971-2080 Sentence denotes As of January 2020, REMAP-CAP was approved and enrolling patients in 52 ICUs in 13 countries in 3 continents.
T11 2081-2182 Sentence denotes In February, it transitioned into pandemic mode with several design adaptations for COVID-19 disease.
T12 2183-2324 Sentence denotes Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.
T13 2325-2389 Sentence denotes Clinical trial registered with ClinicalTrials.gov (NCT02735707).